Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib

Li Zhang; Yongsheng Wang; Lizhu Lin; Yongfeng Yu; Shun Lu

doi:10.1177/17588359231216089

Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib

Ther Adv Med Oncol. 2023 Dec 23:15:17588359231216089. doi: 10.1177/17588359231216089. eCollection 2023.

Authors

Li Zhang¹, Yongsheng Wang², Lizhu Lin³, Yongfeng Yu⁴, Shun Lu⁵

Affiliations

¹ Department of Respiratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
² Department of Oncology, West China Hospital, Sichuan University, Chengdu, China.
³ Department of Oncology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
⁴ Department Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁵ Department Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.

Abstract

Savolitinib is a highly selective mesenchymal-epithelial transition (MET) tyrosine kinase inhibitor (TKI). Based on its significant efficacy shown in clinical studies, savolitinib was conditionally approved for marketing in China on 22 June 2021, for the treatment of advanced non-small cell lung cancer (NSCLC) with MET 14 exon skipping mutation. Additionally, many studies showed that MET TKIs were equally effective in patients with advanced solid tumors with MET gene amplification or MET protein overexpression. Several relevant registered clinical studies are in progress. The most common adverse reactions (ARs) due to savolitinib administration are nausea, vomiting, peripheral edema, pyrexia, and hepatotoxicity. This consensus was developed through two rounds of extensive national surveys involving multidisciplinary experts in China, aiming to guide clinicians to prevent and treat various ARs scientifically, and improve the efficacy of the drug and the quality of life of patients.

Keywords: MET; adverse reactions; consensus; malignant tumor; savolitinib.